Related Experiment Video
Updated: Mar 28, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Silver nanoparticles modulate ABC transporter activity and enhance chemotherapy in multidrug resistant cancer
Dávid Kovács1, Krisztina Szőke1, Nóra Igaz1
1Department of Biochemistry and Molecular Biology, University of Szeged, Szeged, Hungary.
Abstract:
The emergence of multidrug resistant (MDR) cancer phenotypes dramatically attenuates the efficiency of antineoplastic drug treatments often leading to the failure of chemotherapy. Therefore there is an urgent need to engineer new therapeutically useful agents and propose innovative approaches able to defeat resistant cancer cells. Although the remarkable anti-cancer features of silver nanoparticles (AgNPs) have already been delineated their impact on MDR cancer has never been investigated. Herein, we report that AgNPs have notable anti-proliferative effect and induce apoptosis mediated cell death both in drug sensitive and in MDR cancer cells. Furthermore we show evidence that AgNPs exert an inhibitory action on the efflux activity of MDR cancer cells which feature could be exploited to enhance drug accumulation. We verified synergistic interactions of AgNPs with six different antineoplastic agents on drug resistant cells which emphasizes the excellent potential of AgNPs as combinational partners in the chemotherapy of MDR cancer.
From The Clinical Editor:
The treatment of cancer often fails due to the development of multidrug resistant (MDR) cancer cells. Hence, novel approaches are being investigated to combat drug resistant cancer cells. One particular method studied here uses silver nanoparticles (AgNPs). The authors showed that AgNPs had anti-proliferative effect and ?exerted an inhibitory action on ABC transporter. The findings could suggest the possible use of AgNPs in combination with other chemotherapeutic agents in the clinical setting.
Insights
Silver nanoparticles (AgNPs) combat multidrug-resistant (MDR) cancer by inhibiting drug efflux and enhancing chemotherapy. AgNPs show synergistic effects with antineoplastic agents, offering a novel approach against resistant cancer cells.
Area of Science:
- Nanotechnology in oncology
- Cancer biology and drug resistance
Background:
- Multidrug resistance (MDR) in cancer significantly limits chemotherapy efficacy.
- Novel therapeutic strategies are crucial to overcome MDR cancer phenotypes.
- Silver nanoparticles (AgNPs) present a potential new avenue for combating resistant cancers.
Purpose of the Study:
- To investigate the anti-cancer effects of silver nanoparticles (AgNPs) on multidrug-resistant (MDR) cancer cells.
- To explore the potential of AgNPs in combination therapy for MDR cancer.
Main Methods:
- Evaluation of AgNPs' anti-proliferative and apoptosis-inducing effects on drug-sensitive and MDR cancer cells.
- Assessment of AgNPs' impact on the efflux activity of MDR cancer cells.
- Verification of synergistic interactions between AgNPs and various chemotherapeutic agents.
Main Results:
- AgNPs demonstrated significant anti-proliferative activity and induced apoptosis in both drug-sensitive and MDR cancer cells.
- AgNPs inhibited the efflux activity of MDR cancer cells, potentially increasing intracellular drug accumulation.
- Synergistic effects were observed when AgNPs were combined with six different antineoplastic agents against resistant cells.
Conclusions:
- Silver nanoparticles exhibit potent anti-cancer properties against MDR cancer cells.
- AgNPs can enhance the efficacy of existing chemotherapeutic agents by overcoming drug resistance mechanisms.
- AgNPs hold promise as combinational partners in the clinical treatment of multidrug-resistant cancers.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
09:48Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Related Concept Videos
ABC Transporters: Exporter
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules
Treatment Resistant Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters